ECSP11011390A - Compuestos espiro-amidas sustituidas - Google Patents
Compuestos espiro-amidas sustituidasInfo
- Publication number
- ECSP11011390A ECSP11011390A ECSP11011390A ECSP11011390A EC SP11011390 A ECSP11011390 A EC SP11011390A EC SP11011390 A ECSP11011390 A EC SP11011390A EC SP11011390 A ECSP11011390 A EC SP11011390A
- Authority
- EC
- Ecuador
- Prior art keywords
- espiro
- amidas
- substituted compounds
- compounds
- preparation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
El presente invento se relaciona con compuestos sustituidos de espiro-amida, procesos para la preparación de estos, medicamentos que contienen estos compuestos y el uso de los compuestos sustituidos de espiro-amida para la preparación de medicamentos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09004235 | 2009-03-25 | ||
| EP09011708 | 2009-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011390A true ECSP11011390A (es) | 2012-03-30 |
Family
ID=42224836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP11011390 ECSP11011390A (es) | 2009-03-25 | 2011-10-11 | Compuestos espiro-amidas sustituidas |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8455475B2 (es) |
| EP (1) | EP2411381A1 (es) |
| JP (1) | JP2012521377A (es) |
| KR (1) | KR20110137377A (es) |
| CN (1) | CN102365276A (es) |
| AR (1) | AR076148A1 (es) |
| AU (1) | AU2010227802A1 (es) |
| BR (1) | BRPI1013614A2 (es) |
| CA (1) | CA2756532A1 (es) |
| CO (1) | CO6430424A2 (es) |
| EC (1) | ECSP11011390A (es) |
| IL (1) | IL215267A0 (es) |
| MX (1) | MX2011010068A (es) |
| NZ (1) | NZ595293A (es) |
| PE (1) | PE20120833A1 (es) |
| RU (1) | RU2011142618A (es) |
| TW (1) | TW201038572A (es) |
| WO (1) | WO2010108651A1 (es) |
| ZA (1) | ZA201107772B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2623491A3 (en) * | 2009-04-02 | 2014-07-30 | Merck Patent GmbH | Piperidine and piperazine derivatives as autotaxin inhibitors |
| SG183812A1 (en) * | 2010-03-19 | 2012-10-30 | Pfizer | 2,3 dihydro-1h-inden-1-yl- 2,7-diazaspiro [3.5] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor |
| US8809552B2 (en) * | 2011-11-01 | 2014-08-19 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
| HRP20161774T1 (hr) * | 2012-06-13 | 2017-02-24 | F. Hoffmann - La Roche Ag | Novi diazaspirocikloalkan i azaspirocikloalkan |
| BR112015004111A2 (pt) | 2012-09-25 | 2017-07-04 | Hoffmann La Roche | novos derivados bicíclicos |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| AU2014318832B2 (en) | 2013-09-12 | 2018-11-29 | Janssen Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| KR20160087900A (ko) | 2013-11-26 | 2016-07-22 | 에프. 호프만-라 로슈 아게 | 신규한 옥타하이드로-사이클로부타[1,2-c;3,4-c'']다이피롤-2-일 |
| SI3122750T1 (sl) | 2014-03-26 | 2019-12-31 | F. Hoffmann-La Roche Ag | Biciklične spojine kot zaviralci proizvodnje avtotaksina (ATX) in lizofosfatidne kisline (LPA) |
| KR20160128428A (ko) | 2014-03-26 | 2016-11-07 | 에프. 호프만-라 로슈 아게 | 오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서의 축합형 [1,4]다이아제핀 화합물 |
| ES2686326T3 (es) * | 2014-07-15 | 2018-10-17 | Grünenthal GmbH | Derivados de azaspiro(4,5)decano sustituidos |
| MX383931B (es) | 2015-03-11 | 2025-03-14 | Janssen Biopharma Inc | Compuestos de aza-piridona y usos de estos. |
| CN106008503B (zh) * | 2015-03-31 | 2020-09-01 | 齐鲁制药有限公司 | 螺环芳基砜作为蛋白激酶抑制剂 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| JP6886967B2 (ja) | 2015-09-04 | 2021-06-16 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | フェノキシメチル誘導体 |
| AU2016328365B2 (en) | 2015-09-24 | 2020-04-23 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| RU2018112230A (ru) | 2015-09-24 | 2019-10-30 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов atx |
| CN107635995B (zh) | 2015-09-24 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 作为atx抑制剂的二环化合物 |
| JP6877413B2 (ja) | 2015-09-24 | 2021-05-26 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 二重atx/ca阻害剤としての新規な二環式化合物 |
| TW201726678A (zh) | 2015-10-30 | 2017-08-01 | 赫孚孟拉羅股份公司 | 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途 |
| KR20180103053A (ko) * | 2015-12-22 | 2018-09-18 | 비타이 파마슈티컬즈, 인코포레이티드 | 메닌-mll 상호작용의 억제제 |
| MX378995B (es) | 2016-01-13 | 2025-03-11 | Gruenenthal Gmbh | Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. |
| PL3722284T3 (pl) | 2016-01-13 | 2025-03-31 | Grünenthal GmbH | Pochodne 3-((hetero-)arylo)-8-amino-2-okso-1,3-diazaspiro-[4.5]-dekanu |
| LT3402782T (lt) | 2016-01-13 | 2020-10-12 | Grünenthal GmbH | 8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai |
| BR112018068703B1 (pt) | 2016-03-16 | 2024-02-06 | Kura Oncology, Inc. | Inibidores substituídos de menin-mll e métodos de uso |
| JP2019525929A (ja) * | 2016-07-28 | 2019-09-12 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Parkin酵素機能の小分子活性化因子 |
| EP3366683A1 (en) | 2017-02-28 | 2018-08-29 | Acousia Therapeutics GmbH | Cyclic amides, acteamides and ureas useful as potassium channel openers |
| WO2018167113A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
| EP3596059B1 (en) | 2017-03-16 | 2024-04-24 | F. Hoffmann-La Roche AG | Heterocyclic compounds useful as dual atx/ca inhibitors |
| WO2019060365A1 (en) * | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE |
| WO2019200114A1 (en) * | 2018-04-12 | 2019-10-17 | Arbutus Biopharma Corporation | Methods for preparing substituted dihydroindene-4-carboxamide compounds |
| CN111434664A (zh) * | 2019-01-13 | 2020-07-21 | 西南大学 | 亚胺螺环哌啶类化合物的合成及应用 |
| GEAP202316332A (en) | 2021-01-29 | 2023-12-11 | Cedilla Therapeutics Inc | Cdk2 inhibitors and methods of using the same |
| EP4358954A4 (en) | 2021-06-26 | 2025-09-03 | Cedilla Therapeutics Inc | CDK2 INHIBITORS AND METHODS OF USE THEREOF |
| CN113976072B (zh) * | 2021-11-10 | 2024-02-23 | 武汉青风凯默生物医药科技有限公司 | 一种4-甲酰基-n-cbz哌啶的制备装置及方法 |
| JPWO2023210623A1 (es) | 2022-04-28 | 2023-11-02 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1109544A4 (en) * | 1998-09-01 | 2004-10-27 | Bristol Myers Squibb Co | POTASSIUM CHANNEL INHIBITORS AND THEIR METHOD OF USE |
| DE60033071T2 (de) * | 1999-12-06 | 2007-08-23 | Euro-Celtique S.A. | Triazospiroverbindungen mit nociceptin-rezeptoraffinität |
| US20090253908A1 (en) | 2004-03-11 | 2009-10-08 | Glaxo Group Limited | Novel m3 muscarinic acetylchoine receptor antagonists |
| ES2551293T3 (es) | 2004-03-24 | 2015-11-17 | Abbvie Inc. | Inhibidores de quinasas de pirazol tricíclicos |
| CN101080389A (zh) * | 2004-10-15 | 2007-11-28 | 拜尔药品公司 | 具有抗增殖活性的茚满酰胺 |
| BRPI0518281A2 (pt) * | 2004-11-18 | 2008-11-18 | Incyte Corp | inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos |
| WO2006113140A2 (en) * | 2005-04-15 | 2006-10-26 | Elan Pharmaceuticals, Inc. | Novel compounds useful for bradykinin b1 receptor antagonism |
| DE102005030051A1 (de) * | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
| BRPI0613427A2 (pt) * | 2005-07-19 | 2012-10-30 | Merck & Co Inc | composto ou seu sal ou éster, composição farmacêutica, agente terapêutico, e , uso do composto ou seu sal ou éster |
| WO2007101007A2 (en) | 2006-02-23 | 2007-09-07 | Neurogen Corporation | Aryl sulfonyl heterocycles |
| WO2007140383A2 (en) * | 2006-05-30 | 2007-12-06 | Neurogen Corporation | Spirocyclic sulfonamides and related compounds |
| KR20090079914A (ko) | 2006-09-29 | 2009-07-22 | 그뤼넨탈 게엠베하 | 치환된 설폰아미드 유도체 |
| CA2666406A1 (en) | 2006-10-16 | 2008-04-24 | Gruenenthal Gmbh | Substituted sulfonamide derivatives for use as bradykinin 1 receptor modulators |
-
2010
- 2010-03-19 TW TW099108105A patent/TW201038572A/zh unknown
- 2010-03-23 CA CA2756532A patent/CA2756532A1/en not_active Abandoned
- 2010-03-23 KR KR1020117025143A patent/KR20110137377A/ko not_active Withdrawn
- 2010-03-23 RU RU2011142618/04A patent/RU2011142618A/ru not_active Application Discontinuation
- 2010-03-23 AU AU2010227802A patent/AU2010227802A1/en not_active Abandoned
- 2010-03-23 CN CN2010800139828A patent/CN102365276A/zh active Pending
- 2010-03-23 PE PE2011001692A patent/PE20120833A1/es not_active Application Discontinuation
- 2010-03-23 WO PCT/EP2010/001804 patent/WO2010108651A1/en not_active Ceased
- 2010-03-23 NZ NZ595293A patent/NZ595293A/xx not_active IP Right Cessation
- 2010-03-23 EP EP10711343A patent/EP2411381A1/en not_active Withdrawn
- 2010-03-23 MX MX2011010068A patent/MX2011010068A/es active IP Right Grant
- 2010-03-23 JP JP2012501179A patent/JP2012521377A/ja active Pending
- 2010-03-23 BR BRPI1013614A patent/BRPI1013614A2/pt not_active IP Right Cessation
- 2010-03-24 US US12/730,597 patent/US8455475B2/en not_active Expired - Fee Related
- 2010-03-25 AR ARP100100948A patent/AR076148A1/es not_active Application Discontinuation
-
2011
- 2011-09-21 IL IL215267A patent/IL215267A0/en unknown
- 2011-09-22 CO CO11123935A patent/CO6430424A2/es not_active Application Discontinuation
- 2011-10-11 EC ECSP11011390 patent/ECSP11011390A/es unknown
- 2011-10-24 ZA ZA2011/07772A patent/ZA201107772B/en unknown
-
2013
- 2013-04-15 US US13/862,690 patent/US20130231327A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110137377A (ko) | 2011-12-22 |
| RU2011142618A (ru) | 2013-04-27 |
| NZ595293A (en) | 2012-10-26 |
| US8455475B2 (en) | 2013-06-04 |
| CO6430424A2 (es) | 2012-04-30 |
| BRPI1013614A2 (pt) | 2019-09-24 |
| JP2012521377A (ja) | 2012-09-13 |
| PE20120833A1 (es) | 2012-07-23 |
| EP2411381A1 (en) | 2012-02-01 |
| CN102365276A (zh) | 2012-02-29 |
| AR076148A1 (es) | 2011-05-18 |
| CA2756532A1 (en) | 2010-09-30 |
| US20100249095A1 (en) | 2010-09-30 |
| MX2011010068A (es) | 2011-10-06 |
| US20130231327A1 (en) | 2013-09-05 |
| TW201038572A (en) | 2010-11-01 |
| WO2010108651A1 (en) | 2010-09-30 |
| IL215267A0 (en) | 2011-11-30 |
| AU2010227802A1 (en) | 2011-11-10 |
| ZA201107772B (en) | 2012-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11011390A (es) | Compuestos espiro-amidas sustituidas | |
| ECSP13012519A (es) | Compuestos sustituidos de benzamida | |
| SV2018005794A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| ECSP099620A (es) | Derivados de ciclohexano espirociclico | |
| CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
| SV2017005514A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| PA8827101A1 (es) | Derivados de indazoles sustituidos con fenilo o piridinilo | |
| ECSP11011517A (es) | Compuestos antivirales | |
| CO6321189A2 (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
| ECSP11011348A (es) | 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3 | |
| ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
| UY33735A (es) | Compuestos antivirales | |
| ECSP11011347A (es) | Nicotinamida sustituida como moduladores KCNQ2/3 | |
| NI201200023A (es) | Derivados de 5-fluoropirimidinona | |
| CR20120283A (es) | Inhibidor de bromodominio de benzodiazepina | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| CR20110497A (es) | Nuevos anticuerpos anti-alfa5beta1 y sus usos | |
| CL2008003690A1 (es) | Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos. | |
| NI201400042A (es) | 2 - tiopirimidinonas | |
| EA201101116A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
| ECSP11011346A (es) | 3-Amino-2-mercaptoquinolina sustituida como modulador de KCNQ2/3 | |
| ECSP11011345A (es) | 2-mercapto-3-aminopiridina sustituida como moduladores de kcnq2/3 | |
| CO6321288A2 (es) | Sales de compuestos inhibidores de vih | |
| ECSP10010200A (es) | Derivados de pirazol como inhibidores de 5-lo | |
| CL2012001759A1 (es) | Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica. |